Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

Leukemia and lymphoma are cancers that affect the blood or bone marrow. Fifteen percent of people with leukemia have chronic myeloid leukemia (CML), which has seen a 55% jump in new cases over the ...

Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary ...

US regulators’ use of a speedy clearance pathway for a new frontline indication for asciminib for chronic myeloid leukemia (CML) has raised questions due to the number of medications already available ...

Chronic myeloid leukemia may seem to appear suddenly, but new research shows it begins years before diagnosis with an explosive surge of growth. Scientists tracked how a single genetic accident—the ...

Experts on chronic myeloid leukemia discuss how caregivers can collaborate with the health care team and support newly diagnosed patients. In your work with caregivers, how have you seen them ...

Merck has struck a $5.7bn deal to buy Terns Pharmaceuticals, a US biotech developing treatments for a rare form of blood and ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...

Merck said on Wednesday it would buy biotech Terns Pharma for US$6.7 billion, as the drugmaker races to bolster ...

Merck & Co. has agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion, in a deal designed to bolster the ...